News from cytrx corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 30, 2018, 09:00 ET CytRx Corporation to Present at 8th Annual LD Micro Invitational Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. John Caloz, ...

May 17, 2018, 09:00 ET CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that clinical data ...

May 15, 2018, 04:44 ET CytRx Announces Closing of $7.0 Million Registered Direct Offering

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the closing of its...

May 11, 2018, 08:00 ET CytRx Announces $7.0 Million Registered Direct Offering

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered...

May 08, 2018, 08:30 ET CytRx Reports First Quarter 2018 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...

May 07, 2018, 09:00 ET CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric...

May 03, 2018, 08:30 ET CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its Board of...

Apr 30, 2018, 09:00 ET CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that an abstract...

Apr 18, 2018, 08:00 ET CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of...

Apr 09, 2018, 09:00 ET CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric...

Mar 15, 2018, 09:00 ET CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has selected ...

Mar 12, 2018, 09:00 ET CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report...

Mar 05, 2018, 09:00 ET CytRx to Present at the 30th Annual ROTH Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the Company...

Mar 01, 2018, 09:00 ET CytRx Announces Key Addition to Corporate Development Team

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the engagement of...

Feb 22, 2018, 09:00 ET CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that three abstracts ...

Feb 06, 2018, 09:00 ET CytRx Corporation to Present at the 2018 BIO CEO & Investor Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and...

Feb 05, 2018, 09:00 ET CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin ...

Jan 17, 2018, 09:00 ET CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin ...

Jan 03, 2018, 09:00 ET CytRx Corporation to Present at Biotech Showcase 2018

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and...

Dec 07, 2017, 08:00 ET CytRx Corporation Provides Update on Presentations at Upcoming Investor Conferences

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its...

Nov 27, 2017, 08:00 ET CytRx Corporation to Present at Upcoming Investor Conferences

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and...

Nov 17, 2017, 08:00 ET CytRx Corporation Regains Nasdaq Listing Compliance

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it received...

Nov 13, 2017, 08:00 ET CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today provided a business update and ...

Nov 08, 2017, 08:00 ET CytRx Reports Third Quarter 2017 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...

Nov 06, 2017, 08:00 ET CytRx Announces Strategic Realignment of Clinical Development Team

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the strategic...